Development and validation of combined symptom-medication scores for allergic rhinitis*

Simple item page
dc.contributor.authorSousa-Pinto B.
dc.contributor.authorAzevedo L.F.
dc.contributor.authorJutel M.
dc.contributor.authorAgache I.
dc.contributor.authorCanonica G.W.
dc.contributor.authorCzarlewski W.
dc.contributor.authorPapadopoulos N.G.
dc.contributor.authorBergmann K.-C.
dc.contributor.authorDevillier P.
dc.contributor.authorLaune D.
dc.contributor.authorKlimek L.
dc.contributor.authorAnto A.
dc.contributor.authorAnto J.M.
dc.contributor.authorEklund P.
dc.contributor.authorAlmeida R.
dc.contributor.authorBedbrook A.
dc.contributor.authorBosnic-Anticevich S.
dc.contributor.authorBrough H.A.
dc.contributor.authorBrussino L.
dc.contributor.authorCardona V.
dc.contributor.authorCasale T.
dc.contributor.authorCecchi L.
dc.contributor.authorCharpin D.
dc.contributor.authorChivato T.
dc.contributor.authorCosta E.M.
dc.contributor.authorCruz A.A.
dc.contributor.authorDramburg S.
dc.contributor.authorDurham S.R.
dc.contributor.authorDe Feo G.
dc.contributor.authorGerth van Wijk R.
dc.contributor.authorFokkens W.J.
dc.contributor.authorGemicioglu B.
dc.contributor.authorHaahtela T.
dc.contributor.authorIllario M.
dc.contributor.authorIvancevich J.C.
dc.contributor.authorKvedariene V.
dc.contributor.authorKuna P.
dc.contributor.authorLarenas-Linnemann D.E.
dc.contributor.authorMakris M.
dc.contributor.authorMathieu-Dupas E.
dc.contributor.authorMelén E.
dc.contributor.authorMorais-Almeida M.
dc.contributor.authorMösges R.
dc.contributor.authorMullol J.
dc.contributor.authorNadeau K.C.
dc.contributor.authorPham-Thi N.
dc.contributor.authorO’Hehir R.
dc.contributor.authorRegateiro F.S.
dc.contributor.authorReitsma S.
dc.contributor.authorSamolinski B.
dc.contributor.authorSheikh A.
dc.contributor.authorStellato C.
dc.contributor.authorTodo-Bom A.
dc.contributor.authorTomazic P.V.
dc.contributor.authorToppila-Salmi S.
dc.contributor.authorValero A.
dc.contributor.authorValiulis A.
dc.contributor.authorVentura M.T.
dc.contributor.authorWallace D.
dc.contributor.authorWaserman S.
dc.contributor.authorYorgancioglu A.
dc.contributor.authorDe Vries G.
dc.contributor.authorvan Eerd M.
dc.contributor.authorZieglmayer P.
dc.contributor.authorZuberbier T.
dc.contributor.authorPfaar O.
dc.contributor.authorAlmeida Fonseca J.
dc.contributor.authorBousquet J.
dc.date.accessioned2024-07-22T08:04:12Z
dc.date.available2024-07-22T08:04:12Z
dc.date.issued2022
dc.description.abstractBackground: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials. © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
dc.identifier.DOI-ID10.1111/all.15199
dc.identifier.issn01054538
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12594
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Inc
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAsthma
dc.subjectHumans
dc.subjectQuality of Life
dc.subjectReproducibility of Results
dc.subjectRhinitis
dc.subjectRhinitis, Allergic
dc.subjectadolescent
dc.subjectadult
dc.subjectaged
dc.subjectallergic disease
dc.subjectallergic rhinitis
dc.subjectArticle
dc.subjectcluster analysis
dc.subjectcomparative study
dc.subjectconcurrent validity
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectEuropean Quality of Life 5 Dimensions questionnaire
dc.subjectfactor analysis
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedication therapy management
dc.subjectproductivity
dc.subjectquality of life
dc.subjectregression analysis
dc.subjectscoring system
dc.subjectsymptom assessment
dc.subjecttest retest reliability
dc.subjectvalidation study
dc.subjectvisual analog scale
dc.subjectallergic rhinitis
dc.subjectasthma
dc.subjectreproducibility
dc.subjectrhinitis
dc.titleDevelopment and validation of combined symptom-medication scores for allergic rhinitis*
dc.typeArticle

Files

Collections

Scopus Koleksiyonu